Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost
South Africa
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari,
Created on
April 29, 2024
Last modified
April 29, 2024
Page views
24560
Download
2
Documentation in PDF
Metadata
DDI/XML
JSON
- Data files
- SHERPA_Safetydata
select_art (select_art)
Data file: SHERPA_Safetydata
Overview
Valid:
2961
Invalid:
0
Type:
Discrete
Width:
77
Range:
-
Format:
character
Questions and instructions
Categories
| Value | Category | Cases | |
|---|---|---|---|
| No | 1 |
0%
|
|
| Other | 345 |
11.7%
|
|
| Tenofovir DF (TDF); Lamivudine (3TC) & Dolutegravir | 1680 |
56.7%
|
|
| Tenofovir DF (TDF);[Emtricitabine (FTC) or Lamivudine (3TC)]; Efavirenz (EFV) | 935 |
31.6%
|
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.